Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Austria, Industry Worries Over Loss Of EU Medtech NBs

Executive Summary

EU member state Austria has lost its only two medtech notified bodies, which is ringing alarm bells for local medtech industry advocates who fear there will be a loss of momentum and profile for the national medtech ecosystem.

You may also be interested in...



Exec: EU May Lose Out On More Innovation As MDR Pressure On NBs Begins To Bite

The new MDR and IVDR were drafted with highest interests of EU patients in mind, but they may yet have a devastating effect on the EU's speedy access to innovation in general, and on medtech SMEs in particular. That is the view of one Swiss medtech CEO; he also has grave concerns about the loss of EU notified bodies and the impact on manufacturers.

19 Countries Have Submitted Bids To Host The EMA Post-Brexit

Formal offers to host the European Medicines Agency were received from 19 countries by the deadline of July 31. The European Commission will now begin assessing the bids on the basis of six criteria, with a final decision expected in November.

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT105362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel